title: Effects of intraocular or systemic administration of neutralizing antibody against vascular endothelial growth factor on the murine experimental model of retinopathy.
abstract: Vascular endothelial growth factor (VEGF), the strongest known angiogenic cytokine and also a potent enhancer of vascular permeability, is closely associated with diabetic ocular complications and other intraocular neovascular diseases. The therapeutic effect of VEGF-neutralizing antibody on oxygen-induced retinopathy in an experimental murine model of proliferative retinopathy was investigated. Intraocular and systemic injection of the antibody resulted in 46% and 18% reductions in the number of nuclei of newly formed vessels of this model, respectively. The results demonstrated that a neutralizing antibody against VEGF was highly effective in the treatment of intraocular neovascularization and suggested possible modes of therapy in human intraocular neovascular diseases, including diabetic proliferative retinopathy.
authors.affiliation: Department of Internal Medicine, Institute of Clinical Medicine, University of Tsukuba, Japan. hsone@md.tsukuba.ac.jp
authors.forename: H
authors.initials: H
authors.lastname: Sone
authors.forename: Y
authors.initials: Y
authors.lastname: Kawakami
authors.forename: T
authors.initials: T
authors.lastname: Segawa
authors.forename: Y
authors.initials: Y
authors.lastname: Okuda
authors.forename: Y
authors.initials: Y
authors.lastname: Sekine
authors.forename: S
authors.initials: S
authors.lastname: Honmura
authors.forename: T
authors.initials: T
authors.lastname: Segawa
authors.forename: H
authors.initials: H
authors.lastname: Suzuki
authors.forename: K
authors.initials: K
authors.lastname: Yamashita
authors.forename: N
authors.initials: N
authors.lastname: Yamada
mesh_terms: D000818:Animals; D000831:Animals, Newborn; D000906:Antibodies / Q000276:immunology / Q000494:pharmacology*; D003930:Diabetic Retinopathy / Q000628:therapy; D004195:Disease Models, Animal; D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors* / Q000276:immunology*; D005260:Female; D006801:Humans; D007231:Infant, Newborn; D007279:Injections, Subcutaneous; D008222:Lymphokines / Q000037:antagonists & inhibitors* / Q000276:immunology*; D051379:Mice; D008810:Mice, Inbred C57BL; D010100:Oxygen / Q000633:toxicity; D011247:Pregnancy; D011817:Rabbits; D015861:Retinal Neovascularization / Q000628:therapy; D012178:Retinopathy of Prematurity / Q000628:therapy*; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
chemical_list: D000906:Antibodies; D016228:Endothelial Growth Factors; D008222:Lymphokines; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D010100:Oxygen